FDA Approves Ado-Trastuzumab Emtansine for HER2+ Breast Cancer
FDA Approves Ivosidenib for AML
AUA Releases New Guidance for Testicular Cancer, Radiotherapy after Prostatectomy
ACS: More than Half of Americans Report Medical Financial Hardship
AHA Releases Scientific Statement on Cardio-Oncology Rehabilitation
CMS Releases IPPS Proposed Rule
FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
FOA: Optimizing Management & Outcomes for Survivors Moving Into Follow-Up Care
ASCO and ASH Updated Guidelines for Managing Biosimilar ESAs
FDA Approves Erdafitinib for Metastatic Urothelial Carcinoma
FDA Expands Pembrolizumab Indication to Include First-Line NSCLC Treatment
FDA Expands Palbociclib Use to Include Male Breast Cancer Patients
FDA Proposes Policy Changes to Update Mammography Services
FDA Approves Atezolizumab for Small Cell Lung Cancer
CMS Updates Drug Dashboards with Drug Pricing and Spending
NCI Director Norman Sharpless Appointed Acting Commissioner of FDA
FDA Approves Trastuzumab-qyyp as Biosimilar to Herceptin
FDA Approves Atezolizumab Plus Nab-paclitaxel for TNBC
CMS Seeks Input on Eliminating Barriers to Sale of Health Insurance Across State Lines
FDA Approves Trastuzumab and Hyaluronidase-oysk for Breast Cancer
FDA Approves Trifluridine and Tipiracil for Gastric/GEJ Adenocarcinoma
FDA Approves Pembrolizumab for Melanoma
ASBS Recommends Genetic Testing for All Breast Cancer Patients
CMS Releases Proposed NCD for CAR T-cell Therapy
ACCC Joins Groups Expressing Concerns Over CMS' Interpretation of NCD for NGS
HHS Proposes Rule to End Middleman Drug Pricing Rebates
FDA Approves Pemetrexed for Metastatic NSCLC
CMS to Hold Two Webinars on Part D Payment Modernization Model
FDA Approves Ibrutinib Plus Obinutuzumab for CLL/SLL
Medicare Coverage Established for MRD Testing for ALL, Multiple Myeloma
